Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Computational Comparative Pharmacology: Designing Better Drugs for Animals (and Humans)

Modeling and simulation can help veterinarians provide better care for animals and guide research study design thereby maximizing the knowledge gained from research studies whilst minimizing the number of animals used. In this webinar, we looked at how PBPK modeling can be used to predict the absorption, distribution, metabolism, and excretion of drugs in humans and other animal species.

Speaker(s): Ronette Gehring
Solution: Model-informed Drug Development, PBPK Modeling & Simulation, PK/PD Modeling & Simulation
More Info

Making Sense of 6MWT Variability: Developing a Disease Progression Model for DMD

Duchenne Muscular Dystrophy (DMD) is a life-threatening, sex-linked, pediatric rare disease, primarily affecting boys. It is characterized by progressive muscle degeneration, weakness, and eventually functional loss. DMD is caused by a mutation in the dystrophin gene, a protein needed to maintain muscle integrity, and for improving signaling and growth in differentiation of the muscle tissue. […]

Author(s): Lora Hamuro
Solution: PK/PD Modeling & Simulation
Therapeutic Area: Pediatrics, Rare/Orphan Disease
More Info

Using Virtual Twin Technology to Predict Drug Exposure in Individual Patients

In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.

Speaker(s): Tom Polasek
Solution: PBPK Modeling & Simulation
Therapeutic Area: Central Nervous System
More Info

Using Model-informed Drug Development Approaches to Accelerate Orphan Drug Development

Orphan drugs are used to treat rare diseases and disorders. This year marks the 35th anniversary of both the landmark Orphan Drug Act, a law passed by the US FDA that created legal and financial incentives for pharma and biotech to pursue rare disease R&D, and the formation of the National Organization for Rare Disorders […]

Author(s): Maria Saluta
Solution: Clinical Pharmacology Strategy, PBPK Modeling & Simulation, PK/PD Modeling & Simulation
Therapeutic Area: Pediatrics, Rare/Orphan Disease
More Info

A Targeted Approach to Medicine and Dosing—A Necessity for Sustainable Healthcare

President Obama, during his 2015 State of the Union Address, launched the Precision Medicine Initiative “to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care.” The message given to the American people reinforced the critical need to implement precision medicine into […]

Author(s): Maria Saluta
Solution: PBPK Modeling & Simulation
More Info
Learn More LinkedIn Twitter Facebook Email